View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAdvanced Health Intelligence 향후 성장Future 기준 점검 5/6Advanced Health Intelligence (는) 각각 연간 178.9% 및 166.6% 수익과 수익이 증가할 것으로 예상됩니다.핵심 정보178.9%이익 성장률n/aEPS 성장률Healthcare Services 이익 성장22.3%매출 성장률166.6%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트02 Oct 2023최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jul 30Advanced Health Intelligence Ltd(NasdaqCM:AHI) dropped from NASDAQ Composite IndexAHI has been dropped from NASDAQ Composite Index공시 • Apr 16Advanced Health Intelligence Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.9575 million.Advanced Health Intelligence Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.9575 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 29,000,000 Price\Range: AUD 0.0675 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공시 • Feb 27Advanced Health Intelligence Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.2 million.Advanced Health Intelligence Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,000,000 Price\Range: AUD 0.1 Transaction Features: Subsequent Direct Listing공시 • Dec 02Advanced Health Intelligence Ltd to Launch Medically Approved Mobile Phone-Based Atrial Fibrillation AssessmentAdvanced Health Intelligence Ltd. announced that the Company will be expanding the current biometric assessment suite with on-mobile device Atrial Fibrillation (AF) service in quarter 2 of 2024 after signing a binding agreement with QOMPIUM NV. AHI is thrilled to be expanding the biometric capabilities the company is bringing to the global healthcare system with the introduction of AF-Scan. This ground-breaking mobile phone-based solution is set to revolutionise the detection and management of Atrial Fibrillation (AF). This innovative technology is poised to offer unprecedented accessibility and convenience, opening new possibilities in AF monitoring for global populations. With the increasing prevalence of AF and its substantial impact on healthcare systems and economies, AF-Scan will emerge as a critical tool for individuals, healthcare professionals, and public health initiatives. With widespread Approval and Accessibility, Qompium technology has received approval as software as a medical device in multiple countries, including Australia, the European Union (EU), the United Kingdom (UK), the United Arab Emirates (UAE), Saudi Arabia, Singapore, and the United States by the Food and Drug Administration (FDA). This extensive approval further underscores the reliability and credibility of assisting with AF detection and is a unique and sought-after addition to the AHI biometric assessment offering. Atrial Fibrillation (af) is a prevalent cardiac condition with a substantial impact on public health. AHI's BHA harnesses the power of PPG collected via the flashlight and camera on smartphone to provide downstream services such as AF-Scan with the necessary biometric signals. The solution is backed by a medically certified AI algorithm that swiftly analyses the PPG measurements it captures. This analysis generates a comprehensive set of graphical data in the form of a report to be consumed by a physician. One can share this report with physician, making discussions about heart health more productive. AF diagnosis is challenging, often leading to underdiagnosis and misdiagnosis, emphasizing the need for proactive monitoring. AF-Scan is a mobile phone-based solution addressing these challenges. It offers accessibility and convenience, bridging gaps in AF monitoring worldwide. By empowering individuals to monitor their heartythm, AF-Scan aims to reduce the incidence of complications like strokes and heart failure, optimising healthcare spending. This level of accessibility can potentially transform how approach cardiac health. AI will incorporate the AF-Scan into biometric health assessment platform. This integration will further enhance the sensor sets already used across multiple disease categories, encompassing a remarkable 41 intrinsic biomarkers. This synergy will provide individuals with a comprehensive health assessment that goes beyond cardiac health, allowing to offer a holistic view of their well-being. AF-Scan offers a game-changing alternative in a market where traditional AF screening and monitoring methods often involve cumbersome processes and visits to healthcare facilities. By combining the mobile phone with advanced biometric health assessment platform, provide individuals with a powerful tool that empowers them to take control of their health like never before. As the roll out AF-Scan and integrate it into existing platform, are not just launching a product but pioneering a product but pioneering a product.공시 • Nov 06Advanced Health Intelligence Ltd. has filed a Follow-on Equity Offering in the amount of AUD 2.1995 million.Advanced Health Intelligence Ltd. has filed a Follow-on Equity Offering in the amount of AUD 2.1995 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,749,996 Price\Range: AUD 0.11 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 9,245,454 Price\Range: AUD 0.11 Transaction Features: Subsequent Direct Listing공시 • Nov 01Advanced Health Intelligence Ltd. announced delayed 20-F filingOn 10/31/2023, Advanced Health Intelligence Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC.공시 • Oct 19Advanced Health Intelligence Ltd., Annual General Meeting, Nov 17, 2023Advanced Health Intelligence Ltd., Annual General Meeting, Nov 17, 2023, at 10:30 W. Australia Standard Time. Location: Steinepreis Paganin, Level 4, 16 Milligan Street, Perth WA 6000 Perth Western Australia Australia Agenda: To receive and consider the annual financial report of the Company for the financial year ended 30 June 2023 together with the declaration of the Directors, the Director's report, the Remuneration Report and the auditor's report; to consider adoption of remuneration report; to election of director Jacqueline yee; to re-election of director Dato low koon poh; to re-election of director Mike melby; to issue of shares to related party Nicholas prosser; to issue of shares to related party Mike melby; to approval of 7.1A mandate; to adoption of employee securities incentive plan; to ratification of prior issue of lender shares; to ratification of prior issue of consultant shares; to ratification of prior issue of supplier shares; to ratification of prior issue of placement shares listing rule 7.1; to ratification of prior issue of placement shares listing rule 7.1A; to ratification of prior issue of lead manager options; and to consider other issues.공시 • Sep 14Advanced Health Intelligence Ltd. announced that it has received AUD 1.5 million in fundingAdvanced Health Intelligence Ltd. announced a private placement of unsecured convertible loan facility for the gross proceeds of AUD 1,500,000 on September 12, 2023. The loan carry interest rate of 10% per annum and is compounded quarterly in arrears and will mature after 24 months from the date of signing. The investors may elect to redeem the outstanding principal amount and interest on the loans in cash on the Maturity Date. The loans and interest may be converted into fully paid ordinary shares at the investor’s election, at a conversion price equal to AUD 0.30 per share. The transaction is subject to shareholders approval.공시 • Jun 15Advanced Health Intelligence Ltd. has completed a Follow-on Equity Offering in the amount of AUD 5 million.Advanced Health Intelligence Ltd. has completed a Follow-on Equity Offering in the amount of AUD 5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 20,000,000 Price\Range: AUD 0.25 Discount Per Security: AUD 0.015 Transaction Features: Subsequent Direct ListingNew Risk • Jun 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 76% a day. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$11m free cash flow). Share price has been highly volatile over the past 3 months (76% average daily change). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (AU$494k revenue, or US$333k). Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (US$11.3m market cap).공시 • Dec 20Advanced Health Intelligence Ltd. Announces Board ChangesAdvanced Health Intelligence Ltd. announced some changes at the company's Board of Directors. Former wellteq Digital Health Inc. Chair of the Finance and Audit committee, Ms Jacqueline Yee joins AHI's Board of Directors as a non-executive independent Director with effect from 20 December 2022. Ms Yee has an impressive background having spent over 30 years as an institutional finance professional out of New York, London, Amsterdam, Australia and currently resides in Singapore. Throughout her career to date, Ms Yee has been involved in over $25 billion in transaction value with a notable volume of work in the healthcare sector, including restructuring of 27 national hospitals and the drafting of Healthcare Investment Valuation Policy in New Zealand. With the addition of Ms Yee, Dr. Peter Vaughan has stepped down from the Board with effect from 16 December 2022.공시 • Dec 02+ 1 more updateAdvanced Human Imaging Appoints Dr. Peter Vaughan as Non-Executive DirectorAdvanced Human Imaging Limited announced the former Chairman of wellteq, Dr. Peter Vaughan CM, MD, will join the Board of AHI as a non-executive director. Dr. Peter Vaughan, former wellteq chairman is also appointed to the Board of Directors for AHI. Dr. Vaughan has an extensive history in healthcare, corporate and politics recognized by his appointment to the Order of Canada "for his contributions to Canada's health care system, and for his pioneering leadership in the establishment and advancement of digital health". Prior to this he has also held positions as the former Deputy Minister of Health and Wellness, Province of Nova Scotia, an emergency, and family physician and RCAF Flight Surgeon, he also serves as Board Chair of Canada Health Infoway and Chair of the Finance and Audit Committee, Treasurer and Board member of the SCAN-H at the University of Windsor Odette School of Business.공시 • Nov 01Advanced Human Imaging Limited announced delayed 20-F filingOn 10/31/2022, Advanced Human Imaging Limited announced that they will be unable to file their next 20-F by the deadline required by the SEC.공시 • Oct 31Advanced Human Imaging Limited, Annual General Meeting, Nov 29, 2022Advanced Human Imaging Limited, Annual General Meeting, Nov 29, 2022, at 12:00 W. Australia Standard Time. Location: Lucy Mame meeting room QT Perth Hotel 133 Murray Street, Perth Western Australia Australia Agenda: To receive and consider the annual financial report of the Company for the financial year ended 30 June 2022 together with the declaration of the Directors, the Director's report, the Remuneration Report and the auditor's report; to consider adoption of Remuneration Report; to consider election of Director - Dr Katherine Iscoe; to consider election of Director - Peter Goldstein; to consider re-election of Director - Nicholas Prosser; to consider issue of shares to related party - Nicholas Prosser; and to consider other matters.Seeking Alpha • Sep 02Advanced Human Imaging loses 22% premarket on entering into definitive agreement to acquire wellteq Digital HealthAdvanced Human Imaging (NASDAQ:AHI) plummets 22% pre market on a definitive arrangement agreement with wellteq Digital Health (OTCQB:WTEQF) to acquire all of the outstanding shares of wellteq Digital. Pursuant to the terms of the agreement, wellteq shareholders will receive one (1) ordinary share of AHI for every six (6) wellteq common shares held. Both the companies have entered into a loan agreement, whereby AHI has agreed to advance to wellteq up to A$1.2M.공시 • Jun 29Advanced Human Imaging Ltd Appoints Peter Goldstein as Non-Executive DirectorAdvanced Human Imaging Ltd. announced the appointment of Mr. Peter Goldstein as a non-executive director with effect from June 29, 2022. Mr. Goldstein has over 30 years of diverse and global entrepreneurial, client advisory and capital marketexperience. With a background in international business, he has worked across a range of markets andindustries, holding positions including investment banker, chairman, chief executive officer, director andadvisor to public, private, and emerging growth companies. Mr. Goldstein has achieved capital marketobjectives by drawing on his strengths in M&A, strategic planning and transaction structuring, as well as hisown entrepreneurial success. He has steered and completed initial public offerings (IPO), up-listing andreverse merger transactions, secured private placements and designed crowdfunding campaigns. Mr. Goldstein founded Exchange Listing, LLC to provide growth companies with a cost-effective one-stopstrategic planning and implementation service to list on senior exchanges such as NASDAQ, NYSE andNEO. Mr. Goldstein is the Founder and CEO of Grandview Capital Partners Inc., providing M&A, financial,operational, and organizational consulting services to businesses globally in a wide range of industries. MrGoldstein previously founded Grandview Capital Inc., a boutique investment bank, where he served asmanaging director of investment banking.Mr Goldstein began his entrepreneurial career as the Founder and CEO of a specialty food distributor, whichpioneered the farm-to-table organic produce industry in top-tier New York City restaurants. Mr. Goldsteinhas an MBA in International Business from the University of Miami and held Series 7, 24, 79, 99 and 66registrations with FINRA.Mr. Goldstein has been published across the finance industry as well as featured in Forbes as a member ofthe Forbes Finance Council. Mr. Goldstein, a resident of Florida, U.S.A.공시 • Jun 02Advanced Human Imaging Limited to Be Deleted from Other OTCAdvanced Human Imaging Limited's ordinary shares will be deleted from Other OTC effective June 2, 2022. The deletion is due to inactive security.공시 • May 28Advanced Human Imaging Limited Announces Resignation of Edward Greissing Jr as DirectorAdvanced Human Imaging Ltd. announced that Mr. Edward Greissing Jr has resigned from the Board of Directors, with effect from 26 May 2022.공시 • Feb 16Advanced Human Imaging Limited Appoints Dr. Katherine Iscoe as DirectorAdvanced Human Imaging Limited announced that the appointment of Dr. Katherine Iscoe as director. The date of appointment is February 15, 2022.공시 • Feb 15+ 1 more updateAdvanced Human Imaging Limited Announces Executive ChangesAdvanced Human Imaging Limited announced that Dr. Katherine Iscoe, Ph.D., Co-Founder, and former CEO of the company will be rejoining the leadership team as an Executive Director and CEO. The announcements were made as AHI Chairman and CEO, Vlado Bosanac is moving into a strategic role as Head of Strategy and Revenue Growth, effective immediately.이익 및 매출 성장 예측NasdaqCM:AHI - 애널리스트 향후 추정치 및 과거 재무 데이터 (AUD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수6/30/20254013N/AN/A16/30/20249-2N/AN/A112/31/2023-1-17-8-8N/A9/30/20230-15-8-8N/A6/30/20231-13-7-7N/A3/31/20232-11-9-9N/A12/31/20222-10-11-11N/A9/30/20221-15-10-10N/A6/30/20220-20-10-10N/A3/31/20220-22-8-8N/A12/31/20210-23-7-6N/A9/30/20210-19-5-5N/A6/30/20211-14-4-4N/A3/31/20211-11-3-3N/A12/31/20201-8-2-2N/A9/30/20201-7-3-2N/A6/30/20200-5-3-3N/A3/31/20200-5-3-3N/A12/31/20190-5-4-4N/A9/30/20190-5-4-4N/A6/30/20190-4-3-3N/A3/31/20190-4-3-3N/A12/31/20180-4-3-3N/A9/30/20181-9-2-2N/A6/30/20182-14-1-1N/A3/31/20182-14-1-1N/A12/31/20172-13-1-1N/A9/30/20171-8N/A-1N/A6/30/20170-2N/A-2N/A3/31/20170-2N/A-2N/A12/31/20160-2N/A-2N/A9/30/20160-2N/A-2N/A6/30/2016N/A-2N/A-2N/A6/30/20150-1N/A-1N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: AHI 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(2.3%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: AHI (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: AHI 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: AHI 의 수익(연간 166.6%)이 US 시장(연간 11.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: AHI 의 수익(연간 166.6%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: AHI의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/04/29 01:21종가2024/01/31 00:00수익2023/12/31연간 수익2023/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Advanced Health Intelligence Ltd는 1명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Allen KleeMaxim Group
공시 • Jul 30Advanced Health Intelligence Ltd(NasdaqCM:AHI) dropped from NASDAQ Composite IndexAHI has been dropped from NASDAQ Composite Index
공시 • Apr 16Advanced Health Intelligence Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.9575 million.Advanced Health Intelligence Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.9575 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 29,000,000 Price\Range: AUD 0.0675 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공시 • Feb 27Advanced Health Intelligence Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.2 million.Advanced Health Intelligence Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,000,000 Price\Range: AUD 0.1 Transaction Features: Subsequent Direct Listing
공시 • Dec 02Advanced Health Intelligence Ltd to Launch Medically Approved Mobile Phone-Based Atrial Fibrillation AssessmentAdvanced Health Intelligence Ltd. announced that the Company will be expanding the current biometric assessment suite with on-mobile device Atrial Fibrillation (AF) service in quarter 2 of 2024 after signing a binding agreement with QOMPIUM NV. AHI is thrilled to be expanding the biometric capabilities the company is bringing to the global healthcare system with the introduction of AF-Scan. This ground-breaking mobile phone-based solution is set to revolutionise the detection and management of Atrial Fibrillation (AF). This innovative technology is poised to offer unprecedented accessibility and convenience, opening new possibilities in AF monitoring for global populations. With the increasing prevalence of AF and its substantial impact on healthcare systems and economies, AF-Scan will emerge as a critical tool for individuals, healthcare professionals, and public health initiatives. With widespread Approval and Accessibility, Qompium technology has received approval as software as a medical device in multiple countries, including Australia, the European Union (EU), the United Kingdom (UK), the United Arab Emirates (UAE), Saudi Arabia, Singapore, and the United States by the Food and Drug Administration (FDA). This extensive approval further underscores the reliability and credibility of assisting with AF detection and is a unique and sought-after addition to the AHI biometric assessment offering. Atrial Fibrillation (af) is a prevalent cardiac condition with a substantial impact on public health. AHI's BHA harnesses the power of PPG collected via the flashlight and camera on smartphone to provide downstream services such as AF-Scan with the necessary biometric signals. The solution is backed by a medically certified AI algorithm that swiftly analyses the PPG measurements it captures. This analysis generates a comprehensive set of graphical data in the form of a report to be consumed by a physician. One can share this report with physician, making discussions about heart health more productive. AF diagnosis is challenging, often leading to underdiagnosis and misdiagnosis, emphasizing the need for proactive monitoring. AF-Scan is a mobile phone-based solution addressing these challenges. It offers accessibility and convenience, bridging gaps in AF monitoring worldwide. By empowering individuals to monitor their heartythm, AF-Scan aims to reduce the incidence of complications like strokes and heart failure, optimising healthcare spending. This level of accessibility can potentially transform how approach cardiac health. AI will incorporate the AF-Scan into biometric health assessment platform. This integration will further enhance the sensor sets already used across multiple disease categories, encompassing a remarkable 41 intrinsic biomarkers. This synergy will provide individuals with a comprehensive health assessment that goes beyond cardiac health, allowing to offer a holistic view of their well-being. AF-Scan offers a game-changing alternative in a market where traditional AF screening and monitoring methods often involve cumbersome processes and visits to healthcare facilities. By combining the mobile phone with advanced biometric health assessment platform, provide individuals with a powerful tool that empowers them to take control of their health like never before. As the roll out AF-Scan and integrate it into existing platform, are not just launching a product but pioneering a product but pioneering a product.
공시 • Nov 06Advanced Health Intelligence Ltd. has filed a Follow-on Equity Offering in the amount of AUD 2.1995 million.Advanced Health Intelligence Ltd. has filed a Follow-on Equity Offering in the amount of AUD 2.1995 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,749,996 Price\Range: AUD 0.11 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 9,245,454 Price\Range: AUD 0.11 Transaction Features: Subsequent Direct Listing
공시 • Nov 01Advanced Health Intelligence Ltd. announced delayed 20-F filingOn 10/31/2023, Advanced Health Intelligence Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC.
공시 • Oct 19Advanced Health Intelligence Ltd., Annual General Meeting, Nov 17, 2023Advanced Health Intelligence Ltd., Annual General Meeting, Nov 17, 2023, at 10:30 W. Australia Standard Time. Location: Steinepreis Paganin, Level 4, 16 Milligan Street, Perth WA 6000 Perth Western Australia Australia Agenda: To receive and consider the annual financial report of the Company for the financial year ended 30 June 2023 together with the declaration of the Directors, the Director's report, the Remuneration Report and the auditor's report; to consider adoption of remuneration report; to election of director Jacqueline yee; to re-election of director Dato low koon poh; to re-election of director Mike melby; to issue of shares to related party Nicholas prosser; to issue of shares to related party Mike melby; to approval of 7.1A mandate; to adoption of employee securities incentive plan; to ratification of prior issue of lender shares; to ratification of prior issue of consultant shares; to ratification of prior issue of supplier shares; to ratification of prior issue of placement shares listing rule 7.1; to ratification of prior issue of placement shares listing rule 7.1A; to ratification of prior issue of lead manager options; and to consider other issues.
공시 • Sep 14Advanced Health Intelligence Ltd. announced that it has received AUD 1.5 million in fundingAdvanced Health Intelligence Ltd. announced a private placement of unsecured convertible loan facility for the gross proceeds of AUD 1,500,000 on September 12, 2023. The loan carry interest rate of 10% per annum and is compounded quarterly in arrears and will mature after 24 months from the date of signing. The investors may elect to redeem the outstanding principal amount and interest on the loans in cash on the Maturity Date. The loans and interest may be converted into fully paid ordinary shares at the investor’s election, at a conversion price equal to AUD 0.30 per share. The transaction is subject to shareholders approval.
공시 • Jun 15Advanced Health Intelligence Ltd. has completed a Follow-on Equity Offering in the amount of AUD 5 million.Advanced Health Intelligence Ltd. has completed a Follow-on Equity Offering in the amount of AUD 5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 20,000,000 Price\Range: AUD 0.25 Discount Per Security: AUD 0.015 Transaction Features: Subsequent Direct Listing
New Risk • Jun 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 76% a day. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$11m free cash flow). Share price has been highly volatile over the past 3 months (76% average daily change). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (AU$494k revenue, or US$333k). Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (US$11.3m market cap).
공시 • Dec 20Advanced Health Intelligence Ltd. Announces Board ChangesAdvanced Health Intelligence Ltd. announced some changes at the company's Board of Directors. Former wellteq Digital Health Inc. Chair of the Finance and Audit committee, Ms Jacqueline Yee joins AHI's Board of Directors as a non-executive independent Director with effect from 20 December 2022. Ms Yee has an impressive background having spent over 30 years as an institutional finance professional out of New York, London, Amsterdam, Australia and currently resides in Singapore. Throughout her career to date, Ms Yee has been involved in over $25 billion in transaction value with a notable volume of work in the healthcare sector, including restructuring of 27 national hospitals and the drafting of Healthcare Investment Valuation Policy in New Zealand. With the addition of Ms Yee, Dr. Peter Vaughan has stepped down from the Board with effect from 16 December 2022.
공시 • Dec 02+ 1 more updateAdvanced Human Imaging Appoints Dr. Peter Vaughan as Non-Executive DirectorAdvanced Human Imaging Limited announced the former Chairman of wellteq, Dr. Peter Vaughan CM, MD, will join the Board of AHI as a non-executive director. Dr. Peter Vaughan, former wellteq chairman is also appointed to the Board of Directors for AHI. Dr. Vaughan has an extensive history in healthcare, corporate and politics recognized by his appointment to the Order of Canada "for his contributions to Canada's health care system, and for his pioneering leadership in the establishment and advancement of digital health". Prior to this he has also held positions as the former Deputy Minister of Health and Wellness, Province of Nova Scotia, an emergency, and family physician and RCAF Flight Surgeon, he also serves as Board Chair of Canada Health Infoway and Chair of the Finance and Audit Committee, Treasurer and Board member of the SCAN-H at the University of Windsor Odette School of Business.
공시 • Nov 01Advanced Human Imaging Limited announced delayed 20-F filingOn 10/31/2022, Advanced Human Imaging Limited announced that they will be unable to file their next 20-F by the deadline required by the SEC.
공시 • Oct 31Advanced Human Imaging Limited, Annual General Meeting, Nov 29, 2022Advanced Human Imaging Limited, Annual General Meeting, Nov 29, 2022, at 12:00 W. Australia Standard Time. Location: Lucy Mame meeting room QT Perth Hotel 133 Murray Street, Perth Western Australia Australia Agenda: To receive and consider the annual financial report of the Company for the financial year ended 30 June 2022 together with the declaration of the Directors, the Director's report, the Remuneration Report and the auditor's report; to consider adoption of Remuneration Report; to consider election of Director - Dr Katherine Iscoe; to consider election of Director - Peter Goldstein; to consider re-election of Director - Nicholas Prosser; to consider issue of shares to related party - Nicholas Prosser; and to consider other matters.
Seeking Alpha • Sep 02Advanced Human Imaging loses 22% premarket on entering into definitive agreement to acquire wellteq Digital HealthAdvanced Human Imaging (NASDAQ:AHI) plummets 22% pre market on a definitive arrangement agreement with wellteq Digital Health (OTCQB:WTEQF) to acquire all of the outstanding shares of wellteq Digital. Pursuant to the terms of the agreement, wellteq shareholders will receive one (1) ordinary share of AHI for every six (6) wellteq common shares held. Both the companies have entered into a loan agreement, whereby AHI has agreed to advance to wellteq up to A$1.2M.
공시 • Jun 29Advanced Human Imaging Ltd Appoints Peter Goldstein as Non-Executive DirectorAdvanced Human Imaging Ltd. announced the appointment of Mr. Peter Goldstein as a non-executive director with effect from June 29, 2022. Mr. Goldstein has over 30 years of diverse and global entrepreneurial, client advisory and capital marketexperience. With a background in international business, he has worked across a range of markets andindustries, holding positions including investment banker, chairman, chief executive officer, director andadvisor to public, private, and emerging growth companies. Mr. Goldstein has achieved capital marketobjectives by drawing on his strengths in M&A, strategic planning and transaction structuring, as well as hisown entrepreneurial success. He has steered and completed initial public offerings (IPO), up-listing andreverse merger transactions, secured private placements and designed crowdfunding campaigns. Mr. Goldstein founded Exchange Listing, LLC to provide growth companies with a cost-effective one-stopstrategic planning and implementation service to list on senior exchanges such as NASDAQ, NYSE andNEO. Mr. Goldstein is the Founder and CEO of Grandview Capital Partners Inc., providing M&A, financial,operational, and organizational consulting services to businesses globally in a wide range of industries. MrGoldstein previously founded Grandview Capital Inc., a boutique investment bank, where he served asmanaging director of investment banking.Mr Goldstein began his entrepreneurial career as the Founder and CEO of a specialty food distributor, whichpioneered the farm-to-table organic produce industry in top-tier New York City restaurants. Mr. Goldsteinhas an MBA in International Business from the University of Miami and held Series 7, 24, 79, 99 and 66registrations with FINRA.Mr. Goldstein has been published across the finance industry as well as featured in Forbes as a member ofthe Forbes Finance Council. Mr. Goldstein, a resident of Florida, U.S.A.
공시 • Jun 02Advanced Human Imaging Limited to Be Deleted from Other OTCAdvanced Human Imaging Limited's ordinary shares will be deleted from Other OTC effective June 2, 2022. The deletion is due to inactive security.
공시 • May 28Advanced Human Imaging Limited Announces Resignation of Edward Greissing Jr as DirectorAdvanced Human Imaging Ltd. announced that Mr. Edward Greissing Jr has resigned from the Board of Directors, with effect from 26 May 2022.
공시 • Feb 16Advanced Human Imaging Limited Appoints Dr. Katherine Iscoe as DirectorAdvanced Human Imaging Limited announced that the appointment of Dr. Katherine Iscoe as director. The date of appointment is February 15, 2022.
공시 • Feb 15+ 1 more updateAdvanced Human Imaging Limited Announces Executive ChangesAdvanced Human Imaging Limited announced that Dr. Katherine Iscoe, Ph.D., Co-Founder, and former CEO of the company will be rejoining the leadership team as an Executive Director and CEO. The announcements were made as AHI Chairman and CEO, Vlado Bosanac is moving into a strategic role as Head of Strategy and Revenue Growth, effective immediately.